Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 348

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Comparison of 18F-Fluoro-L-DOPA, 18F-Fluoro-Deoxyglucose, and 18F-Fluorodopamine PET and 123I-MIBG Scintigraphy in the Localization of Pheochromocytoma and Paraganglioma

Timmers, Henri J. L. M., Chen, Clara C., Carrasquillo, Jorge A., Whatley, Millie, Ling, Alexander, Havekes, Bastiaan, Eisenhofer, Graeme, Martiniova, Lucia, Adams, Karen T., Pacak, Karel · 2009 · The Journal of Clinical Endocrinology & Metabolism

Abstract

Context: Besides 123 I-metaiodobenzylguanidine (MIBG), positron emission tomography (PET) agents are available for the localization of paraganglioma (PGL), including 18 F-3,4-dihydroxyphenylalanine (DOPA), 18 F-fluoro-2-deoxy-D-glucose ( 18 F-FDG), and 18 F-fluorodopamine ( 18 F-FDA).Objective: The objective of the study was to establish the optimal approach to the functional imaging of PGL and examine the link between genotype-specific tumor biology and imaging. Design: This was a prospective observational study.Intervention: There were no interventions.Patients: Fifty-two patients (28 males, 24 females, aged 46.8 Ϯ 14.2 yr): 20 with nonmetastatic PGL (11 adrenal), 28 with metastatic PGL (13 adrenal), and four in whom PGL was ruled out; 22 PGLs were of the succinate dehydrogenase subunit B (SDHB) genotype.Main Outcome Measures: Sensitivity of 18 F-DOPA, 18 F-FDG, and 18 F-FDA PET, 123 I-MIBG scintigraphy, computed tomography (CT), and magnetic resonance imaging (MRI) for the localization of PGL were measured.Results: Sensitivities for localizing nonmetastatic PGL were 100% for CT and/or MRI, 81% for 18 F-DOPA PET, 88% for 18 F-FDG PET/CT, 78% for 18 F-FDA PET/CT, and 78% for 123 I-MIBG scintigraphy.For metastatic PGL, sensitivity in reference to CT/MRI was 45% for 18 F-DOPA PET, 74% for 18 F-FDG PET/CT, 76% for 18 F-FDA PET/CT, and 57% for 123 I-MIBG scintigraphy.In patients with SDHB metastatic PGL, 18 F-FDA and 18 F-FDG have a higher sensitivity (82 and 83%) than 123 I-MIBG (57%) and 18 F-DOPA (20%).Conclusions: 18 F-FDA PET/CT is the preferred technique for the localization of the primary PGL and to rule out metastases.Second best, equal alternatives are 18 F-DOPA PET and 123 I-MIBG scintigraphy.For patients with known metastatic PGL, we recommend 18 F-FDA PET in patients with an unknown genotype, 18 F-FDG or 18 F-FDA PET in SDHB mutation carriers, and 18 F-DOPA or 18 F-FDA PET in non-SDHB patients.(J Clin Endocrinol Metab 94: 4757-4767, 2009) P aragangliomas (PGLs) derive from sympathetic chro- maffin tissue in adrenal and extraadrenal abdominal or thoracic locations or from parasympathetic tissue of the head and neck (1).The terms pheochromocytoma and glomus tumor refer to respective adrenal PGL and head and neck PGL (2, 3).The majority of abdominal and thoracic PGLs produce catecholamines (4), whereas head and neck PGLs usually do not.This study focused on sympathetic PGL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2009-1248

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 39

  1. Lenders, 2005, Phaeochromocytoma., Lancet, 366, 665, 10.1016/S0140-6736(05)67139-5 · DOI · Paper page
  2. Pacak, 2005, Pheochromocytoma, In: De Groot LJ, Jameson JL, eds. Textbook of endocrinology. Philadelphia: Elsevier Saunders, Inc.;, 2501
  3. Lenders, 2002, Biochemical diagnosis of pheochromocytoma: which test is best?, JAMA, 287, 1427, 10.1001/jama.287.11.1427 · DOI · Paper page
  4. Ilias, 2005, New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas., Trends Endocrinol Metab, 16, 66, 10.1016/j.tem.2005.01.007 · DOI
  5. Shulkin, 1999, Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-d-glucose PET., Radiology, 212, 35, 10.1148/radiology.212.1.r99jl3035 · DOI · Paper page
  6. Taniguchi, 2001, Metastases of predominantly dopamine-secreting phaeochromocytoma that did not accumulate meta-iodobenzylguanidine: imaging with whole body positron emission tomography using 18F-labelled deoxyglucose., Eur J Surg, 167, 866, 10.1080/11024150152717733 · doi:10.1080/11024150152717733
  7. Timmers, 2007, Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma., J Clin Oncol, 25, 2262, 10.1200/JCO.2006.09.6297 · DOI · Paper page
  8. Bhatia, 2008, (123)I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation., Clin Endocrinol (Oxf), 69, 181, 10.1111/j.1365-2265.2008.03256.x · DOI
  9. Hoegerle, 2002, Pheochromocytomas: detection with 18F DOPA whole body PET—initial results., Radiology, 222, 507, 10.1148/radiol.2222010622 · DOI · Paper page
  10. Hoegerle, 2003, 18F-DOPA positron emission tomography for the detection of glomus tumours., Eur J Nucl Med Mol Imaging, 30, 689, 10.1007/s00259-003-1115-3 · DOI · Paper page
  11. Pacak, 2001, A “pheo” lurks: novel approaches for locating occult pheochromocytoma., J Clin Endocrinol Metab, 86, 3641
  12. Pacak, 2001, 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma., Hypertension, 38, 6, 10.1161/01.HYP.38.1.6 · DOI · Paper page
  13. Harst, 2001, [(123)I]-metaiodobenzylguanidine and [(111)In]-octreotide uptake in benign and malignant pheochromocytomas., J Clin Endocrinol Metab, 86, 685
  14. Van Der Horst-Schrivers, 2006, Iodine-123 metaiodobenzylguanidine scintigraphy in localising phaeochromocytomas—experience and meta-analysis., Anticancer Res, 26, 1599
  15. Amar, 2005, Genetic testing in pheochromocytoma or functional paraganglioma., J Clin Oncol, 23, 8812, 10.1200/JCO.2005.03.1484 · DOI · Paper page
  16. Kaji, 2007, The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome., Eur J Endocrinol, 156, 483, 10.1530/EJE-06-0712 · doi:10.1530/eje-06-0712
  17. Linnoila, 1990, Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features., Hum Pathol, 21, 1168, 10.1016/0046-8177(90)90155-X · DOI · Paper page
  18. Timmers, 2007, The effects of carbidopa on uptake of 6–18F-fluoro-l-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma., J Nucl Med, 48, 1599, 10.2967/jnumed.107.042721 · DOI
  19. Eisenhofer, 2001, The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines., Pharmacol Ther, 91, 35, 10.1016/S0163-7258(01)00144-9 · DOI · Paper page
  20. Pearse, 1969, The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept., J Histochem Cytochem, 17, 303, 10.1177/17.5.303 · DOI · Paper page
  21. Belhocine, 2006, 18FDG PET in oncology: the best and the worst, Int J Oncol, 28, 1249
  22. Pauwels, 2000, Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies., J Cancer Res Clin Oncol, 126, 549, 10.1007/PL00008465 · DOI · Paper page
  23. Lynn, 1985, Pheochromocytoma and the normal adrenal medulla: improved visualization with I-123 MIBG scintigraphy., Radiology, 155, 789, 10.1148/radiology.155.3.4001380 · DOI
  24. Becherer, 2004, Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET., J Nucl Med, 45, 1161
  25. Hoegerle, 2001, Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors., Radiology, 220, 373, 10.1148/radiology.220.2.r01au25373 · DOI · Paper page
  26. Nanni, 2006, 18F-DOPA PET/CT and neuroendocrine tumours., Eur J Nucl Med Mol Imaging, 33, 509, 10.1007/s00259-006-0079-5 · doi:10.1007/s00259-006-0079-5
  27. Brink, 2006, Fluorine-18 DOPA PET imaging of paraganglioma syndrome., Clin Nucl Med, 31, 39, 10.1097/01.rlu.0000191577.39458.a0 · DOI
  28. Imani, 2009, 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas., J Nucl Med, 50, 513, 10.2967/jnumed.108.058396 · DOI
  29. Fiebrich, 2009, 18F-DOPA PET is superior to conventional imaging with 123I-metaiodobenzylguanidine scintigraphy, CT, and MRI in localizing tumors causing catecholamine excess., J Clin Endocrinol Metab, 94, 3922, 10.1210/jc.2009-1054 · DOI
  30. Taieb, 2008, The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas., Clin Endocrinol (Oxf), 69, 580, 10.1111/j.1365-2265.2008.03257.x · DOI
  31. Mackenzie, 2007, The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma., Eur J Endocrinol, 157, 533, 10.1530/EJE-07-0369 · DOI
  32. Ilias, 2003, Superiority of 6-[18F]fluorodopamine positron emission tomography versus [131I]metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma., J Clin Endocrinol Metab, 88, 4083, 10.1210/jc.2003-030235 · DOI · Paper page
  33. Mann, 2006, [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma., Ann Surg Oncol, 13, 187, 10.1245/ASO.2006.04.022 · DOI
  34. Eisenhofer, 2001, Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes., J Clin Endocrinol Metab, 86, 1999, 10.1210/jcem.86.5.7496 · DOI · Paper page
  35. Timmers, 2007, Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas., J Clin Endocrinol Metab, 92, 779, 10.1210/jc.2006-2315 · DOI · Paper page
  36. Huynh, 2005, Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2., Eur J Endocrinol, 153, 551, 10.1530/eje.1.01987 · DOI
  37. Taieb, 2009, 18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature?, J Nucl Med, 50, 711, 10.2967/jnumed.108.060731 · DOI
  38. Ilias, 2008, Comparison of 6–18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma., J Nucl Med, 49, 1613, 10.2967/jnumed.108.052373 · DOI
  39. Fanti, 2008, Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET., Biomed Pharmacother, 62, 667, 10.1016/j.biopha.2008.01.010 · DOI

Cited by

See all 348

Metadata

Authors
Timmers, H. J. L. M., Chen, C. C., Carrasquillo, J. A., Whatley, M., Ling, A., Havekes, B., Eisenhofer, G., Martiniova, L., Adams, K. T., & Pacak, K.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2009-12-01
Volume
94
Issue
12
Pages
4757-4767
ISSN
  • 0021-972X
  • 1945-7197
Cited by
348
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.